



Drug Prior Authorization Committee Meeting

<u>Date</u>	<u>Time</u>	<u>Location</u>
June 16, 2022	10:00am – 3:00pm (CST)	MHD Building 615 Howerton Ct, Jefferson City, MO 65101 and WebEx

[* Click HERE for Meeting Documents *](#)

Committee Members Present:

Conrad Balcer, DO, Chair
J.K. Sturgeon, PharmD, BCPS
Laura Kingsley, PharmD
Maya Moody, DO, FAAP
Morgan Sperry, PharmD

Committee Members Absent:

Angeline Stanislaus, MD
Matthew Stinson, MD

MO HealthNet Staff Present:

Joshua Moore, PharmD, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Angela Wilson, Pharmacy Operations
Manager
Olivia Rush, PharmD, Program Integrity
Pharmacist
Elizabeth Sissom, RN, Clinical Management
Lisa Smith, RFP Coordinator
Carmen Burton, Administrative Assistant
Timothy Kling, MD, Acting Medical Director
Elizabeth Short, Program Development
Specialist
Connie Sutter, Fiscal Manager
Keri Ballew, Drug Rebate Unit Supervisor
Vicki Benz, Drug Rebate Medicaid Specialist
Pat Borgmeyer, Drug Rebate Medicaid
Specialist

Racheal Rachau, Benefit Program Senior
Specialist
Jamie Herzing, Benefit Program Senior
Specialist
Nikki Ashley, Pharmacy Program Specialist
Nicolas York, PMP, Information Systems
Project Manager

Contractors Present:

April Ash, PharmD, Conduent
Blake Shrout, PharmD, AAHIVP, Conduent
Jennifer Colozza, PharmD, Conduent
Megan Fast, PharmD, Conduent
Paul Fung, PharmD, Conduent
Chelsea Pendleton, RN, BSN, Wipro
Geri Roling, RN, Wipro
Mandi Nilges, RN, Wipro

Others Present:

Audrey Rattan
Beth
Bill Eicholzer
Brooke Wilkins
Charles Trebilcock
Dana Pipkin
Doug Wood
Emily Kalmer
Erin Hohman
Folger Tuggle
Gary Gottesman
Jason Demuth
Jeana Ring
Jenny Carrell
Jerid Maddox
John Bullard
Jonathan Leesman
Kathrin Kucharski
Kurt Hendrickson
Megan Bell
Melissa Basil
Michael Estoos
Michael Holmes
Michael Hooks
Michele Shirley
Nila Stevens
Robert Pearce
Roberto Pedraza
Shari
Shelly Somrock
Suzanne Morgan

Tami Sova
Theresa Martinez
Tom Arnhart
Wardl7

<p>Welcome, Announcements and Introductions</p>	<p>Conrad Balcer, Committee Chair, called the meeting to order.</p> <p>Joshua Moore, MHD Director of Pharmacy, introduced himself along with Jamie Herzing, MHD’s new Benefit Program Senior Specialist. Joshua facilitated the meeting on behalf of the MO HealthNet Division.</p> <p>Laura Kingsley also introduced her pharmacy students, IsaBella Duffett, Marley Anderson and Lauren Nigus. Geri Roling introduced additional Wipro staff, Mandi Nilges.</p>
<p>Minutes Review</p>	<p>Discussion: Minutes were reviewed from the March meeting.</p> <p>Decision: The Committee voted to accept these approved minutes with no revisions.</p>
<p>Pharmacy Program and Budget Update</p>	<p>Elizabeth Short and Joshua Moore presented a brief power point of the Pharmacy Program and Budget Updates. Information presented included:</p> <ul style="list-style-type: none"> - July 2021-May 2022 Eligibles by Group - July 2021-May 2022 Expenditures by Enrollment Group - July 2021-May 2022 Expenditures by Service - FY22 Pharmacy Spend vs Total Medicaid Spend - Oct 2021-May 2022 Medicaid Expansion Participants, Expenditures, and Claim Count - July 2021 – June 2022 Pharmacy Expenditures - Pharmacy Program Top 4 Drug Classes per FY - Hep C FY 2018 – FYTD 2022 - Mavyret Expenditures July 2019 – June 2022 - FY2019 – FYTD2023 Rare Disease Expenditures Per Day - Trikafta Expenditures FY 22 - Pharmacy Dashboard Drug Reimbursement Trends 2021-2022 - Pharmacy Dashboard Drug Reimbursement Per User Per Month Trends 2021-2022 - Additional discussions arose around: <ul style="list-style-type: none"> o Project HepCure public facing dashboard

Old Business	
Old Business	<p>Joshua Moore discussed the Edit Implementation Schedule and the criteria for Previously Approved Clinical Edits, Step Therapies and Prior Authorizations.</p> <p>These handouts were also provided to all attendees and will be posted to the Division's web page: https://dss.mo.gov/mhd/cs/advisory/drugpa/meeting.htm</p>
New Business	
New Drug Review	<p>Discussion:</p> <ul style="list-style-type: none"> - Olivia Rush reviewed the new products identified for the quarter and the recommended status within the pharmacy program. <ul style="list-style-type: none"> o A listing of products recommended for open access, clinical edit, step therapy, preferred drug list (PDL), or continue prior authorization was emailed to the Committee for discussion and action. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the presented new drug recommendations with no revisions.</p>

Clinical and Fiscal Edit Review

Clinical & Fiscal Edits With No Annual Changes

Discussion:

- Joshua Moore introduced the edits for discussion to the Committee which included:
 - o Ampyra
 - o Botulinum Toxin
 - o Duchenne Muscular Dystrophy (DMD)
 - o Emsam
 - o Gamifant
 - o Immunoglobulin
 - o Koselugo
 - o Luxturna
 - o Narcolepsy Inhibitors
 - o Neuromyelitis Optica Spectrum Disorder (NMOSD)
 - o Nuedexta
 - o Oxandrin
 - o Palforzia
 - o Palynziq
 - o Ranexa
 - o Reblozyl
 - o Selective Serotonin Reuptake Inhibitors (SSRI)
 - o Synagis
 - o Tepezza
 - o Tolvaptan
 - o Transthyretin-Mediated Amyloidosis (ATTR)
 - o Xcopri
 - o Zometa
- Discussion around the SSRI Clinical Edit:
 - o Reports from providers included many issues with the diagnosis codes requirements for pediatric participants
 - There was an ask for MHD to provide a list of payable codes to the providers. Josh to follow up with Dr. Moody.
 - It was discussed that the issue may lie with both the provider and the pharmacy not utilizing the appropriate payable diagnosis code.

	<ul style="list-style-type: none"> ▪ Discussions made to leave edit as is without changes to the diagnosis code requirements and move forward with more education to both the provider and pharmacy communities. - Crysvida was originally presented in the section on the agenda but has been moved and addressed below. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Besremi Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> ○ Michael Hooks with Pharmaessentia <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">CAR-T Cell Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Crysvida Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - Discussions around Dr. Gottesman paper/journal - Clarifications were provided on the continuation of therapy criteria (normalization of serum phosphorus levels) along with the prior authorization lengths (4 vs 12 months) - Decision made to approve with the presented criteria, including updated, with MHD expected to have Rare Disease review the criteria at the next meeting - Public comment provided by: <ul style="list-style-type: none"> ○ Tom Arnhart with Ultragenyx ○ Dr. Gary Gottesman with Washington University <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p align="center">Enjaymo Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Nila Stevens with Sanofi <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Enzyme Deficiency, Select Agents Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Jason Demuth with Agios Pharmaceuticals on Pyrukynd <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Iron, Injectable Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p align="center">Manufacturers Requiring Prior Authorization Fiscal Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

<p>Psychotropic Medications Polypharmacy Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Parathyroid Hormone (PTH) and Bone Resorption Suppression Related Agents Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - Discussion arose around the denial criteria for Reclast. Per the package insert and standard practice, participants with end stage renal disease should not receive the medication. - Recommended denial criteria: <ul style="list-style-type: none"> o For Reclast: Documented diagnosis of end stage renal disease - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with the changes in blue.</p>
<p>Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - No public comment provided. <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>
<p>Vyvgart Clinical Edit</p>	<p>Discussion:</p> <ul style="list-style-type: none"> - Joshua Moore introduced the edit for discussion to the Committee. - No other discussion. - Public comment provided by: <ul style="list-style-type: none"> o Shelly Somrock with Argenx <p>Decision: The Committee voted to accept the recommended criteria with no additional revisions.</p>

Other Business	
Program Utilization Information – Conduent Update	<p>Jennifer Colozza with Conduent presented the following items for review:</p> <ul style="list-style-type: none"> - Top 25 Drugs by Paid Amount 3rd Quarter 2022 (January, February, March) - Top 25 Drugs by Paid Number 3rd Quarter 2022 (January, February, March) - Call Center User Statistics May 2022 - CyberAccess Logging Information - New Drug Statistics May 2022
MO HealthNet Pharmacy Overview	<p>Joshua Moore, Angela Wilson and Olivia Rush provided a presentation titled “MHD Pharmacy Overview”.</p> <ul style="list-style-type: none"> - No other discussion. - No public comment provided.
Adjournment	<p>Morgan Sperry motioned for the meeting to be adjourned. The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. The next meeting of the Drug Prior Authorization Committee is scheduled via hybrid meeting (in person and WebEx) on Thursday, September 15, 2022.</p>

NEXT MEETING: Thursday, September 15, 2022
615 Howerton Court, Conference Room 202
Jefferson City, MO 65109 and WebEx

Roll Call for June 16, 2022							
	<u>Committee Member</u>						
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody
March 2021 Minutes	Y	MY	Y	A	A	SY	Y
New Drug Review	Y	SY	MY	A	A	Y	Y
Clinical & Fiscal Edits With No Annual Changes	Y	Y	Y	A	A	SY	MY
Besremi Clinical Edit	Y	Y	MY	A	A	SY	Y
CAR-T Cell Clinical Edit	Y	SY	Y	A	A	MY	Y
Crysvita Clinical Edit	Y	SY	Y	A	A	MY	Y
Enjaymo Clinical Edit	Y	MY	Y	A	A	SY	Y
Enzyme Deficiency, Select Agents Clinical Edit	Y	MY	Y	A	A	SY	Y
Iron, Injectable Clinical Edit	Y	MY	SY	A	A	Y	Y
Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit	Y	SY	MY	A	A	Y	Y
Manufacturers Requiring Prior Authorization Fiscal Edit	Y	Y	MY	A	A	SY	Y
Psychotropic Medications Polypharmacy Clinical Edit	Y	SY	Y	A	A	Y	MY
Parathyroid Hormone (PTH) and Bone Resorption Suppression Related Agents Clinical Edit	Y	SY	Y	A	A	MY	Y

Roll Call for June 16, 2022							
	<u>Committee Member</u>						
<u>Action Item</u>	Conrad Balcer	Laura Kingsley	Morgan Sperry	Angeline Stanislaus	Matthew Stinson	J.K. Sturgeon	Maya Moody
Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Clinical Edit	Y	Y	Y	A	A	MY	SY
Targeted Immune Modulators, Small Molecule Janus Kinase (JAK) Inhibitors Clinical Edit	Y	MY	Y	A	A	SY	Y
Vyvgart Clinical Edit	Y	Y	MY	A	A	SY	Y
Motion to Close	Y	Y	MY	A	A	SY	Y
Adjournment	Y	MY	Y	A	A	SY	Y

Roll Call Abbreviations: A-Absent; AL-Alternate; R-Ratify; M-Motion; S-Second; Y-Yes; N-No; AB-Abstain